EXHIBIT 99.1 Claritev Reports Fourth Quarter and Full Year 2024 Results with Initial Guidance for Full Year 2025 NEW YORK, NY — February 25, 2025 — Claritev Corporation ("Claritev" or the "Company") (NYSE: MPLN), formerly known as MultiPlan, a technology, data and insights company focused on making healthcare more affordable, transparent and fair for all, today reported financial results for the fourth quarter and full year ended December 31, 2024. Chairman, CEO and President Travis Dalton said, "We are cel ...

MultiPlan Corporation (MPLN) - The consensus EPS estimate for the quarter has remained unchanged over the last 30 days [1] - The stock price rallied 15.5% in the last trading session to close at $14.70, driven by notable trading volume [3] - The stock has gained 76.6% over the past four weeks [3] - The company is expected to post a quarterly loss of $2.33 per share, representing a year-over-year change of +2.9% [5] - Revenues are expected to be $236.74 million, down 3% from the year-ago quarter [5] - The recent price increase is attributed to investor optimism surrounding the company's decision to consolidate its cloud infrastructure on Oracle Cloud Infrastructure (OCI) as part of its digital transformation strategy [4] Medpace (MEDP) - The consensus EPS estimate for the upcoming report has increased by +0.9% over the past month to $2.97, representing a +20.7% change from the same period last year [2] - The stock closed the last trading session 0.3% higher at $352.01 [1] - Over the past month, the stock has returned 1.4% [1] Industry Context - MultiPlan belongs to the Zacks Medical Services industry [1] - Medpace is another stock in the same industry [1]

Debt and Capital Structure - As of September 30, 2024, the company's long-term debt totaled $4,569.060 million, a decrease from $4,600.030 million as of December 31, 2023[78] - The company purchased and canceled $21.1 million of Senior Convertible PIK Notes during the nine months ended September 30, 2024, resulting in a gain on extinguishment of $5.9 million[78] - The interest rate for Term Loan B was 9.57% as of September 30, 2024[78] - The company is exploring ways to optimize its capital structure to support its transformation into a data and technology-focused entity in healthcare[79] - The fair value of long-term debt as of September 30, 2024, was estimated at $3,059.946 million[88] - The company has irrevocable letters of credit totaling $7.9 million outstanding as of September 30, 2024, related to real estate lease agreements and a captive insurance subsidiary[94] Financial Performance - The company reported impairment charges of $361.6 million for goodwill and $1,434.4 million for long-lived intangible assets for the nine months ended September 30, 2024[91] - The Company reported a net loss of $391,450 thousand for the three months ended September 30, 2024, compared to a net loss of $24,145 thousand for the same period in 2023[102] - The net loss per share was $(24.25) for the three months ended September 30, 2024, compared to $(1.49) for the same period in 2023[102] - The weighted average number of shares outstanding was 16,143,520 for the three months ended September 30, 2024, slightly down from 16,161,095 in the same period of 2023[102] Stock and Legal Matters - The Company has authorized a stock repurchase program of up to $100.0 million, extended through December 31, 2024, with $25.6 million spent as of September 30, 2024[99] - Legal expenses related to ongoing litigation amounted to $23 thousand and $82 thousand for the three and nine months ended September 30, 2024, respectively[103] - The Company has accrued for legal fees and contingencies, reflecting significant management judgment in estimating potential liabilities[98] - The Company intends to vigorously defend against antitrust lawsuits centralized in the Northern District of Illinois[97] Other Financial Activities - The fair value of Private Placement Warrants and Unvested Founder Shares was recorded at $1,000 as of September 30, 2024, down from $477,000 as of December 31, 2023[82] - The company recognized losses of $87,000 related to the change in fair value of Private Placement Warrants and Unvested Founder Shares for the three months ended September 30, 2024[83] - The company received $9.8 million in recoveries from insurers related to a settled litigation during the three months ended September 30, 2024[96] - As of September 30, 2024, prepaid expenses from related parties were $6 thousand, down from $36 thousand as of December 31, 2023[104] Market Risks - There were no material changes in market risks as of September 30, 2024, compared to the 2023 Annual Report[211]

MultiPlan Corporation (MPLN) came out with a quarterly loss of $1.85 per share versus the Zacks Consensus Estimate of a loss of $2.37. This compares to loss of $2.40 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 21.94%. A quarter ago, it was expected that this company would post a loss of $1.60 per share when it actually produced a loss of $1.20, delivering a surprise of 25%.Over the last four quarters, the company has surpa ...

Group 1 - MultiPlan Corporation (MPLN) shares increased by 9% to close at $7.87, following a notable trading volume, despite a 21.7% loss over the past four weeks [1] - The partnership with the National Rural Health Association is fostering optimism, leveraging over 40 years of combined expertise to enhance healthcare quality and reduce costs in rural areas [2] - The upcoming quarterly report is expected to show a loss of $2.40 per share, with revenues projected at $230.91 million, reflecting a 4.9% decline from the previous year [3] Group 2 - The consensus EPS estimate for MultiPlan has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without earnings estimate revisions [4] - MultiPlan is categorized under the Zacks Medical Services industry, where Teladoc (TDOC) has shown a 23.7% return in the past month, closing at $8.41 [4] - Teladoc's EPS estimate has decreased by 2.1% to -$0.29, representing a 17.1% change compared to the previous year [5]

Financial Data and Key Metrics Changes - Second quarter revenue was $233.5 million, a decrease of 1.9% from Q2 2023 and effectively flat sequentially [28] - Adjusted EBITDA was $146.7 million in Q2 2024, down 3.9% from $152.7 million in the prior year quarter and down 0.1% from $146.8 million in Q1 2024 [34] - Adjusted EBITDA margin was 62.8% in Q2 2024, up 20 basis points from Q1 2024 but down from 64.2% in the prior year quarter [35] - Full year 2024 revenue guidance revised to $935 million to $955 million, down from prior guidance of $1.0 billion to $1.03 billion [36] Business Line Data and Key Metrics Changes - Network-based revenues declined 0.9% sequentially, driven by continued softness in complementary network and Property and Casualty businesses [29] - Analytics-based revenues were essentially flat sequentially, with strength in Data iSight offset by softness in NSA volumes [29] - Payment and Revenue Integrity revenues declined 1.4% sequentially, driven by softness in Prepayment Clinical Negotiation business [30] Market Data and Key Metrics Changes - Total second quarter build charges increased 9% sequentially to $45.3 billion, and identified potential savings increased 8% sequentially to $6.2 billion [31] - Identified potential savings in the core percentage of savings revenue model increased 3% sequentially to $4.4 billion [31] - Revenue yield declined about 31 basis points sequentially for the overall business, with a decline of about 14 basis points in the core percentage of savings revenue model [32][33] Company Strategy and Development Direction - The company is engaged in a 5-year strategic and resource planning exercise to assess market potential and sharpen new product development [14] - A focus on transforming into a data and technology-forward organization with an aggressive growth mindset is emphasized [21] - The company aims to increase its total addressable market and diversify its customer base by serving national and regional payer clients more aggressively [21] Management's Comments on Operating Environment and Future Outlook - Management acknowledged that financial results have not met expectations and emphasized the need for improvement [25] - The company is confident in its core business despite anticipated attrition from a larger client impacting growth until mid-2025 [37] - Management expressed optimism about the long-term prospects and the potential for sustainable growth through improved execution and product offerings [28][57] Other Important Information - A noncash impairment charge of $553.7 million was recorded due to the estimated fair value of goodwill being less than its carrying value [38] - The company ended the quarter with $49 million of unrestricted cash and emphasized a focus on organic investments and debt reduction [39][40] Q&A Session Summary Question: Guidance for the second half and potential cost savings - Management indicated cautious optimism for the second half, with expectations of modest improvement in core revenues but volatility in revenue yield [43][45] Question: Slower commercial traction on new products - Management clarified that the sales cycle for new products is taking longer than anticipated, but the pipeline remains robust [46] Question: Details on the 3% headwind to revenues in 2025 - Management noted that this headwind is related to a strategic decision by one of their larger clients, not indicative of a broader trend [47][48] Question: Revenue yield volatility - Management explained that while there has been volatility in revenue yield, they expect some normalization as client credits wash through the system [50][52] Question: Long-term growth expectations - Management reaffirmed the long-term growth targets of 4% to 5% for core out-of-network growth, with potential for higher growth with new products [55][57]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended March 31, 2024 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39228 MULTIPLAN CORPORATION (Exact Name of Registrant as Specified in Its Charter) (State or other jurisdiction of incorp ...

Financial Data and Key Metrics Changes - First quarter revenue was $234.5 million, a decrease of 0.9% from Q1 2023 and a decrease of 3.9% sequentially, falling just shy of the low end of guidance due to a claims volume disruption caused by a cyber outage [62][58] - Adjusted EBITDA for the first quarter was $146.8 million, down 6.1% from $156.3 million in the prior year quarter and down 6.4% from $156.8 million in Q4 2023, with a margin of 62.6% [69][58] - The company recorded non-cash impairment charges of $516.4 million for goodwill and $2.7 million for intangibles, impacting GAAP earnings results [72][91] Business Line Data and Key Metrics Changes - Network-based revenues declined 11.6% sequentially, driven largely by the claims volume disruption, while Payment and Revenue Integrity revenues declined 0.6% sequentially [63][64] - Analytics-based revenues grew 5.0% year-over-year, but overall analytics-based revenues fell 2.1% sequentially due to the claims volume disruption [84][83] - The core percentage of savings revenue model, which constitutes approximately 90% of revenues, saw a revenue yield decline of about 10 basis points, impacting revenues by approximately $4.4 million [68][62] Market Data and Key Metrics Changes - Total first quarter bill charges decreased 4% sequentially to $41.5 billion, with identified potential savings decreasing 3% sequentially to $5.7 billion [85] - In the core commercial health plan segment, bill charges decreased 6% sequentially to $18.3 billion, and identified potential savings decreased 3% sequentially to $5.4 billion [85] - The company noted that larger hospital systems were able to quickly switch to alternative clearinghouses, mitigating some of the disruption effects [66] Company Strategy and Development Direction - The company aims to enhance its operational framework with a focus on clarity, alignment, and accountability, establishing over 30 corporate key performance indicators [53][52] - There is a commitment to organic product development and the introduction of new data and decision science products to serve clients across the healthcare continuum [56][40] - The company plans to focus on debt reduction and organic investments while deemphasizing M&A in the near term [28][29] Management's Comments on Operating Environment and Future Outlook - Management acknowledged external pressures and macro uncertainty in healthcare but expressed optimism about the opportunities these challenges present [2][5] - The company expects revenue growth to accelerate in the second half of the year, maintaining its guidance for fiscal year 2024 despite the shortfall in Q1 results [71][90] - Management emphasized the importance of continuing to serve clients and the healthcare ecosystem, reinforcing the company's mission to reduce healthcare costs [45][30] Other Important Information - The company identified $23 billion in potential medical cost savings across all products in 2023, pricing $15.4 million in out-of-network claims through its platform [31][32] - The average revenue per claim across out-of-network pricing services in 2023 was $44 per claim [32] - The company has a strong focus on enhancing its product offerings and expanding into adjacent markets [108][110] Q&A Session Summary Question: Impact of recent lawsuit on go-to-market strategy - Management confirmed that there would be no change in the go-to-market strategy despite the recent lawsuit, continuing to aggressively target core and adjacent markets [9][10] Question: Changes in management's view on self-insured employer side - Management indicated that there has not been a significant behavior switch among employer plan sponsors, and they are focusing on shifting the business model towards more subscription-type offerings [11][12] Question: Clarification on claims volume disruption and its impact - Management explained that the claims volume disruption was pervasive and affected all payer clients, with expectations for normalization in the second half of April [20][24] Question: Demand for NSA-related products - Management noted ongoing discussions with clients regarding NSA-related products, indicating that clients are moving ahead despite uncertainties [25][26] Question: Long-term growth plans and performance indicators - Management reaffirmed commitment to the 2023-2024 growth plan and emphasized the importance of operational excellence and innovation in driving future growth [111][112]

EXHIBIT 99.1 MultiPlan Reports First Quarter 2024 Results NEW YORK, NY — May 8, 2024 — MultiPlan Corporation ("MultiPlan" or the "Company") (NYSE: MPLN), a leading value-added provider of data analytics and technology-enabled end-to-end cost management, payment and revenue integrity solutions to the U.S. healthcare industry, today reported financial results for the first quarter ended March 31, 2024. "As you heard me say a just few months ago, I joined as CEO because I saw an incredible opportunity to help ...

Financial Data and Key Metrics Changes - For Q4 2023, revenues were $244.1 million, an increase of 0.5% from Q3 and up 1.3% year-over-year despite challenging comparisons due to contract renewals [8][74] - Full year 2023 revenues totaled $961.5 million, down 10.9% from the previous year, primarily due to contract renewals and a decline in COVID-related claim savings [34][75] - Adjusted EBITDA for Q4 2023 was $156.8 million, down 2.9% from the prior year quarter but up 3% sequentially [25][33] - The adjusted EBITDA margin for Q4 2023 improved to 64.2%, up 150 basis points from the prior quarter but down from 67% in Q4 2022 [25][56] Business Line Data and Key Metrics Changes - Network-based revenues declined 8.1% or $4.6 million compared to Q3 2023, largely due to customer adjustments in the complementary network business [17] - Analytics-based revenues grew 3.2% sequentially, driven by strong volumes in Data iSight and NSA services [47] - Payment and Revenue Integrity revenues increased 3.2% sequentially, attributed to strength in Discovery Health lines of business [47] Market Data and Key Metrics Changes - Total billed charges in Q4 increased 2% sequentially to $43.4 billion, with identified potential savings rising 2.3% to $5.9 billion [48] - In the core commercial health plan segment, billed charges were up 5% sequentially to $19.4 billion, with identified potential savings increasing 2.2% [48] Company Strategy and Development Direction - The company is focusing on enhancing its core services and expanding its HST platform, with a goal to solidify market leadership in NSA services and expand into Data & Decision Science Services [58] - A new curated network concept is being developed to target specific geographic markets with high demand for cost-effective healthcare solutions [2][22] - The company plans to introduce additional models focused on high-cost claimants and the senior population to add value for Medicare Advantage plans [65] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's growth trajectory, highlighting the successful execution of the growth plan and the potential for accelerated growth in 2024 and beyond [10][27] - The management acknowledged the challenges posed by the healthcare industry's evolving landscape, including regulatory pressures and changing consumer demands [45][68] - The company anticipates 2024 revenues of $1.0 billion to $1.03 billion, representing a growth of approximately 4% to 7% from 2023 [50] Other Important Information - The company has made significant strides in reducing debt, repurchasing or repaying $362 million in face value of debt over the last five quarters [55][84] - The adjusted EBITDA margin for the full year 2023 was 64.3%, down from 71.2% in 2022, reflecting lower revenue and higher expenses [57][97] Q&A Session Summary Question: Impact of out-of-network segment in 2023 - Management indicated that the out-of-network segment had a 9% headwind in 2023 due to contract renewals, affecting all products [108] Question: Demand for cost containment products in Medicare - Management noted increased demand for Data and Decision Sciences products tailored to meet the needs of the Medicare market [109] Question: Details on curated networks - Management explained that curated networks would be geographically based and focused on specific customer segments or chronic diseases [111] Question: Medical cost inflation guidance - Management stated that while long-term expectations are around 4% to 5%, near-term guidance is more conservative due to upcoming renewals in the healthcare ecosystem [112]